De­ter­mined to build the lead­ing biotech play­er in a new R&D space, Steven Holtz­man lines up $55M for the next stage at Deci­bel

There are no big phar­mas or large cap biotechs build­ing a pipeline of drugs for hear­ing loss. So Steven Holtz­man wants to build a lead­ing play­er in the field from scratch. And now he and the team at Deci­bel have an ex­tra $55 mil­lion of cash to take the next step or two in that jour­ney.

This new round brings the Deci­bel CEO’s cash re­serves to more than $100 mil­lion at the Boston-based biotech, fund­ing plans to grow the staff from 65 to 100 or more as Holtz­man con­tin­ues his mis­sion to build out “the world’s first ful­ly in­te­grat­ed” hear­ing drug dis­cov­ery and de­vel­op­ment plat­form.

Holtz­man aims to have a clear shot at first-mover ad­van­tage in grow­ing the lead­ing biotech in the field. And lack of cash isn’t go­ing to be an is­sue — at least for now.

It’s ear­ly days at Deci­bel, to be sure, but Holtz­man says their first drug — to ad­dress the hear­ing loss caused by a ther­a­py — is in Phase I, just bare­ly. IND en­abling work is com­ing up on an­oth­er drug and Holtz­man — who en­joys be­ing out­spo­ken on many top­ics — isn’t the least bit shy in say­ing that “we have put to­geth­er the lead­ing ef­fort in gene ther­a­py in the hear­ing space.”

Be­ing first in gene ther­a­py aimed at the ear isn’t go­ing to be easy, says the CEO. It re­quires plen­ty of orig­i­nal vec­tor de­sign work to build a de­liv­ery ve­hi­cle that can car­ry the nec­es­sary pack­age where it’s need­ed. And that pi­o­neer­ing ef­fort has to be done at Deci­bel.

“We think in three broad buck­ets,” says Holtz­man, tick­ing them off: Pro­tect­ing against an “in­sult” to hear­ing, like a drug; work­ing with con­gen­i­tal hear­ing loss and re­pair­ing the dam­age to hear­ing that oc­curs over a life­time.

Third Rock Ven­tures, GV and SR One, the in­vestors who got him start­ed with a Se­ries A, came back to jump in­to the ex­pand­ed syn­di­cate, along with Re­gen­eron, which added an eq­ui­ty in­vest­ment for Deci­bel when it struck a strate­gic col­lab­o­ra­tion with Holtz­man and his team. The new in­vestors in­clude Lau­ra Dem­ing’s Longevi­ty, which has been lay­ing bets on com­pa­nies in­volved in an­ti-ag­ing ther­a­pies. 

Fore­site Cap­i­tal, Besse­mer Ven­ture Part­ners and Schroder Ad­veq al­so all came on board, along with some un­named in­vestors, buy­ing in­to Holtz­man’s no­tion that an epi­dem­ic of hear­ing loss has cre­at­ed the per­fect op­por­tu­ni­ty for Deci­bel to get out front and stay there.

George Scan­gos, Holtz­man’s old boss at Bio­gen who al­so moved on to launch his own biotech, is mov­ing up from his board seat to the chair­man’s role. At this stage of the game, says the CEO, it’s time to have an in­de­pen­dent chair­man guid­ing things at the board ta­ble, in­stead of a VC in clas­sic start­up fash­ion.


Im­age: Steven Holtz­man. DECI­BEL

Novartis CEO Vas Narasimhan [via Bloomberg/Getty]

I’m not per­fect: No­var­tis chief Vas Narasimhan al­most apol­o­gizes in the wake of a new cri­sis

Vas Narasimhan has warily stepped up with what might pass as something close to a borderline apology for the latest scandal to engulf Novartis.

But he couldn’t quite get there.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Levi Garraway. Broad Institute via Youtube

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

We found out Monday morning where Levi Garraway was headed after he left Eli Lilly as head of oncology R&D a few days ago. Roche named Garraway as their new chief medical officer, replacing Sandra Horning, who they say is retiring from the company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street analysts that cover Sarepta $SRPT are an upbeat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or offer explanations when an odd setback occurs — as happened recently with a safety signal that was ‘erroneously’ reported last week.

Ritu Baral Cowen
Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Saqib Islam. CheckRare via YouTube

Spring­Works seeks $115M to push Pfiz­er drugs across fin­ish line while Sat­suma sells mi­graine play in $86M IPO

SpringWorks and Satsuma — both biotech spinouts that have closed B rounds in April — are loading up with IPO cash to boost their respective late-stage plans.
SpringWorks

Bain-backed SpringWorks is the better-known company of the two, and it’s gunning for a larger windfall of $115 million to add to $228 million from previous financings. In the process, the Stamford, CT-based team is also drawing the curtains on the partnerships it has in mind for the pair of assets it had initially licensed from Pfizer.

Mi­nor­i­ty racial groups con­tin­ue to be dis­mal­ly rep­re­sent­ed in can­cer tri­als — study

Data reveal that different racial and ethnic groups — by nature and/or nurture — can respond differently in terms of pharmacokinetics, efficacy, or safety to therapeutics, but this disparity is not necessarily accounted for in clinical trials. A fresh analysis of the last decade of US cancer drug approvals suggests the trend continues, cementing previous research that suggests oncology trials are woefully under-representative of the racial makeup of the real world.

Van­da shares slide af­ter FDA spurns their big end­point and re­jects a pitch on jet lag re­lief

Back in the spring of last year, Vanda Pharmaceuticals $VNDA served up a hot stew of mixed data for a slate of endpoints related to what they called clear evidence that their melatonin sleep drug Hetlioz (tasimelteon) could help millions of travelers suffering from jet lag.

Never mind that they couldn’t get a planned 90 people in the study, settling for 25 instead; Vanda CEO Mihael H. Polymeropoulos said they were building on a body of data to prove it would help jet-lagged patients looking for added sleep benefits. And that, they added, would be worth a major upgrade from the agency as they sought to tackle a big market.

Jim Mellon [via YouTube]

Health­i­er, longer lifes­pans will be a re­al­i­ty soon­er than you think, Ju­ve­nes­cence promis­es as it clos­es $100M round

Earlier this year, an executive from Juvenescence-backed AgeX predicted the field of longevity will eventually “dwarf the dotcom boom.” Greg Bailey, the UK-based anti-aging biotech’s CEO, certainly hopes so.

On Monday, Juvenescence completed its $100 million Series B round of financing. The company is backed by British billionaire Jim Mellon — who wrote his 400-page guide to investing in the field of longevity shortly after launching the company in 2017. Bailey, who served as a board director for seven years at Medivation before Pfizer swallowed the biotech for $14 billion, is joined by Declan Doogan, an industry veteran with stints at Pfizer $PFE and Amarin $AMRN.

AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,500+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.